40 years since the advent of the "small pill" in 1981, musk baoxin pill has once again attracted the attention of experts. Recently, 150 experts and scholars in China's cardiovascular field gathered in the form of "offline + online" to conduct in-depth discussions on the launch of the "Chinese Expert Consensus on the Treatment of Coronary Heart Disease and Angina of Coronary Heart Disease" version 2.0 - "Expert Consensus on the Treatment of Coronary Heart Disease by Musk Heart Pills".
Academician Chen Keji of Xiyuan Hospital of China Academy of Chinese Medical Sciences said at the launch meeting that traditional Chinese medicine has a long history of treating coronary heart disease, and as a representative drug for the treatment of coronary heart disease by combining traditional Chinese and Western medicine, musk baoxin pills have accumulated nearly 40 years of application experience. In 2018, the "Chinese Expert Consensus on the Treatment of Coronary Heart Disease and Angina of Coronary Heart Disease" was officially released, which played an important role in standardizing and guiding the clinical application of Musk Heart Pills. In recent years, more high-quality research evidence of musk baoxin pills has been published, especially the MUST study published in the English edition of the Chinese Medical Journal at the beginning of this year, which confirms the clinical value of musk baoxin pills, and it is believed that the National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine and the Cardiovascular Disease Professional Committee of the Chinese Medical Doctor Association Integrative Medicine Physicians Branch jointly promote the consensus update, which will better promote the standardized use of musk Baoxin pills.
Under the guidance of Professor Dai Ruihong of Huashan Hospital affiliated to Fudan University, Academician Chen Keji of the Chinese Academy of Sciences, Academician Zhang Boli of the Chinese Academy of Engineering, and Academician Gao Runlin of the Chinese Academy of Engineering, the writing of the "Chinese Expert Consensus on the Treatment of Coronary Heart Disease and Angina of Coronary Heart Disease" was launched in 2016 and officially published in 2018, which systematically reviewed and summarized the pharmacological effects, clinical efficacy and safety evidence of musk baoxin pills.
Since 2017, evidence-based evidence for the treatment of coronary heart disease by musk baoxin pills has continued to emerge, including 491 new articles in Chinese journals, 19 journals in Chinese medical associations, and 36 articles in English journals. In addition, musk heart pills have been included in the recommendation of coronary heart disease treatment drugs by more than ten guidelines and consensus. In view of this, in order to better support clinical practice with evidence-based evidence, the launch of the "Expert Consensus on the Treatment of Coronary Heart Disease with Musk Heart Pills" is imminent.
On the main points of this consensus update, Professor Shi Haiming of Huashan Hospital affiliated to Fudan University introduced that more and more evidence-based evidence, especially the release of MUST research, provides a solid foundation for the clinical application of musk heart pills in the treatment of coronary heart disease, and this consensus update will be based on these new evidences to organize cardiovascular traditional Chinese and Western medicine experts across the country to collect and discuss opinions extensively and in depth, and the writing and revision process will last 6 months, and it is expected that in April 2022, the "Musk Heart Pills Treatment of Coronary Heart Disease Expert Consensus" will be officially released.
Experts and scholars across the country affirmed this consensus update. Experts mentioned that as the largest clinical study of traditional Chinese medicine in line with international norms, the MUST study took cardiac and cerebrovascular events as the main research endpoint, and proved the clinical value of musk heart pills through rigorous research design and scientific clinical data. In this consensus update, MUST research should be highlighted, so as to provide guidance and reference for the future development of evidence-based research in traditional Chinese medicine.
According to reports, the MUST study, led by Academician Ge Junbo of Zhongshan Hospital Affiliated to Fudan University and Professor Fan Weihu of Huashan Hospital Affiliated to Fudan University, is a multi-center, randomized, double-blind, placebo-controlled Phase IV clinical trial, and all endpoint events are independently reviewed by the endpoint event review committee led by Academician Chen Keji.
The study covered 22 provinces, municipalities directly under the central government and autonomous regions across the country, with a total of 97 tertiary hospitals participating, a total of 2673 patients included, and 8 follow-up visits were completed, lasting 24 months. The study's observational indicators covered the "hard endpoint" major cardiovascular adverse events (MACE) and the "soft endpoint" Seattle angina Scale (SAQ), which was registered as a clinical trial in China and the United States.
The results showed that in terms of MACE, the incidence of MACE after two years of treatment in the experimental group (musk heart pills combined with standard treatment) and control group (placebo combined standard therapy) was 1.9% and 2.6%, respectively. Among them, the incidence of MACE in the experimental group was reduced by 26.9% compared with the control group at 24 months, suggesting the characteristics of the long-term effect of musk heart pills.
In addition, subgroup analysis showed that the use of musk pills in women and patients with BMI <24 significantly reduced the risk of MACE events, indicating that musk pills benefited more in women and in both BMI <24 populations.
From the advent of this small pill in 1981, to the official release of the "Chinese Expert Consensus on the Treatment of Coronary Heart Disease and Angina of Coronary Heart Disease" in 2018, to the national science and technology progress award in 2019, to the debut of the MUST research results in the "Chinese Medical Journal English Edition" in January 2021, to the launch of the "Musk Baoxin Pill Treatment of Coronary Heart Disease Expert Consensus" in September this year, over the past 40 years, the research of Musk Baoxin Pill has always adhered to the modernization and internationalization development strategy and goals. Zhou Junjie, president of Shanghai Hehuang Pharmaceutical, said with emotion that Shanghai hehuang pharmaceutical industry has been established for 20 years, and has always adhered to the modernization and international development of traditional Chinese medicine, and musk baoxin pills are one of the representative drugs, especially from the second prize of the national scientific and technological progress award in 2018 to the publication of MUST evidence-based research results in 2021, musk baoxin pills from evidence-based evidence to clinical application, out of an evidence-based road with both inheritance and development, hoping that the consensus will help doctors apply musk baoxin pills better and more standardized in the future to benefit more patients.
Author: Tang Wenjia Wang Baolong
Editor: Tang Wenjia
Image source: Respondent
![Yang Yuxing went to Luojia Town to supervise grain production and procurement on the spot[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)